Advertisement

American Journal of Cardiovascular Drugs

, Volume 4, Issue 1, pp 43–55 | Cite as

The Use of Vitamin K in Patients on Anticoagulant Therapy

A Practical Guide
  • Thomas HanslikEmail author
  • Jacques Prinseau
Therapy In Practice

Abstract

Anticoagulation with antivitamin K (AVK) is very effective for primary and secondary prevention of thromboembolic events. However, questions persist about the risks and management of over-anticoagulation. For reversal of excessive anticoagulation by warfarin, AVK withdrawal, oral or parenteral vitamin K administration, prothrombin complex or fresh frozen plasma may be used, depending on the excess of anticoagulation, the existence and site of active bleeding, patient characteristics and the indication for AVK. In over-anticoagulated patients, vitamin K aims at rapid lowering of the international normalized ratio (INR) into a safe range to reduce the risk of major bleeding and therefore improving patient outcome without exposing the patient to the risk of thromboembolism due to overcorrection, resistance to AVK, or an allergic reaction to the medication.

The risk of bleeding increases dramatically when the INR exceeds 4.0–6.0, although the absolute risk of bleeding remains fairly low, <5.5 per 1000 per day. Patient characteristics, including advanced age, treated hypertension, history of stroke, and concomitant use of various drugs, affect the risk of bleeding. The absolute risk of thromboembolism associated with overcorrection appears to be in the same range as the risk of bleeding due to over-anticoagulation. The use of vitamin K in patients with warfarin over-anticoagulation lowers excessively elevated INR faster than withholding warfarin alone; however, it has not been clearly demonstrated that vitamin K treatment does, in fact, lower the risk of major hemorrhage.

As vitamin K administration via the intravenous route may be complicated by anaphylactoid reactions, and via the subcutaneous route by cutaneous reactions, oral administration is preferred. A dose of 1–2.5mg of oral phytomenadione (vitamin K1), reduces the range of INR from 5.0–9.0 to 2.0–5.0 within 24–48 hours, and for an INR >10.0, a dose of 5mg may be more appropriate. Overcorrection of the INR or resistance to warfarin is unlikely if the above doses of vitamin K are used. Vitamin K is less effective for over-anticoagulation after treatment with acenocoumarol or phenprocoumon than after treatment with warfarin.

Keywords

Warfarin International Normalize Ratio Major Hemorrhage Warfarin Therapy Phenprocoumon 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

We are grateful to Shéhérazade Ouaret, MD, of the French Health Security Agency, AFSSAPS, for her help in collecting national pharmacovigilance information. No sources of funding were used to assist in the preparation of this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this manuscript.

References

  1. 1.
    Gilman GA, Rall TW, Nies AS, Taylor P, editors. Goodman and Gilman’s the pharmacological basis of therapeutics, 88th edition. New York: Pergamon Press, 1990Google Scholar
  2. 2.
    Keller C, Matzdorff AC, Kemkes-Matthes B. Pharmacology of warfarin and clinical implications. Semin Thromb Hemost 1999; 25(1): 13–6PubMedCrossRefGoogle Scholar
  3. 3.
    Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med 1996; 156(4): 409–16CrossRefGoogle Scholar
  4. 4.
    Cannegieter SC, Rosendaal FR, Wintzen AR, et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995; 333(1): 11–7PubMedCrossRefGoogle Scholar
  5. 5.
    Ansell J, Hirsh J, Dalen J. Managing oral anticoagulant therapy. Chest 2001; 119(1 Suppl.): 22S–38SPubMedCrossRefGoogle Scholar
  6. 6.
    Nitu IC, Perry DJ, Lee CA. Clinical experience with the use of clotting factor concentrates in oral anticoagulation reversal. Clin Lab Haematol 1998; 20(6): 363–7PubMedCrossRefGoogle Scholar
  7. 7.
    Cartmill M, Dolan G, Byrne JL, et al. Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgical emergencies. Br J Neurosurg 2000; 14(5): 458–61PubMedCrossRefGoogle Scholar
  8. 8.
    Makris M, Greaves M, Phillips WS, et al. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 1997; 77(3): 477–80PubMedGoogle Scholar
  9. 9.
    Baglin T. Management of warfarin (coumarin) overdose. Blood Rev 1998; 12(2): 91–8PubMedCrossRefGoogle Scholar
  10. 10.
    Wilson SE, Douketis JD, Crowther MA. Treatment of warfarin-associated coagulopathy: a physician survey. Chest 2001; 120(6): 1972–6PubMedCrossRefGoogle Scholar
  11. 11.
    Hirsh J. Reversal of the anticoagulant effects of warfarin by vitamin K1. Chest 1998; 114(6): 1505–8PubMedCrossRefGoogle Scholar
  12. 12.
    Sweeney KG, Gray DP, Evans P, et al. Anticoagulation therapy: bleeding and thromboembolic complications. Lancet 1996; 348(9039): 1456–7PubMedCrossRefGoogle Scholar
  13. 13.
    Schenk JF, Morsdorf S, Pindur G, et al. Analysis and occurrence of adverse events with oral anticoagulant therapy. Semin Thromb Hemost 1999; 25(1): 65–71PubMedCrossRefGoogle Scholar
  14. 14.
    Levine MN, Raskob G, Landefeld S, et al. Hemorrhagic complications of anticoagulant treatment. Chest 2001; 119(1 Suppl.): 108S–21SPubMedCrossRefGoogle Scholar
  15. 15.
    Gage BF, Cardinalli AB, Albers GW, et al. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA 1995; 274(23): 1839–45PubMedCrossRefGoogle Scholar
  16. 16.
    Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996; 348(9025): 423–8PubMedCrossRefGoogle Scholar
  17. 17.
    Glover JJ, Morrill GB. Conservative treatment of over-anticoagulated patients. Chest 1995; 108(4): 987–90PubMedCrossRefGoogle Scholar
  18. 18.
    Hylek EM, Chang YC, Skates SJ, et al. Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. Arch Intern Med 2000; 160(11): 1612–7PubMedCrossRefGoogle Scholar
  19. 19.
    van der Meer FJ, Rosendaal FR, Vandenbroucke JP, et al. Bleeding complications in oral anticoagulant therapy: an analysis of risk factors. Arch Intern Med 1993; 153(13): 1557–62PubMedCrossRefGoogle Scholar
  20. 20.
    Casais P, Luceros AS, Meschengieser S, et al. Bleeding risk factors in chronic oral anticoagulation with acenocoumarol. Am J Hematol 2000; 63(4): 192–6PubMedCrossRefGoogle Scholar
  21. 21.
    Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial hemorrhage: facts and hypotheses. Stroke 1995; 26(8): 1471–7PubMedCrossRefGoogle Scholar
  22. 22.
    Ogg MS, Brennan P, Meade T, et al. CYP2C9*3 allelic variant and bleeding complications [letter]. Lancet 1999; 354(9184): 1124PubMedCrossRefGoogle Scholar
  23. 23.
    Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998; 105(2): 91–9PubMedCrossRefGoogle Scholar
  24. 24.
    Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 1993; 95(3): 315–28PubMedCrossRefGoogle Scholar
  25. 25.
    Fihn SD, McDonell M, Martin D, et al. Risk factors for complications of chronic anticoagulation: a multicenter study. Warfarin Optimized Outpatient Follow-up Study Group. Ann Intern Med 1993; 118(7): 511–20PubMedGoogle Scholar
  26. 26.
    McMahan DA, Smith DM, Carey MA, et al. Risk of major hemorrhage for outpatients treated with warfarin. J Gen Intern Med 1998; 13(5): 311–6PubMedCrossRefGoogle Scholar
  27. 27.
    Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994; 120(11): 897–902PubMedGoogle Scholar
  28. 28.
    Brigden ML, Kay C, Le A, et al. Audit of the frequency and clinical response to excessive oral anticoagulation in an out-patient population. Am J Hematol 1998; 59(1): 22–7PubMedCrossRefGoogle Scholar
  29. 29.
    Wehinger C, Stollberger C, Langer T, et al. Evaluation of risk factors for stroke/ embolism and of complications due to anticoagulant therapy in atrial fibrillation. Stroke 2001; 32(10): 2246–52PubMedCrossRefGoogle Scholar
  30. 30.
    Petitti DB, Strom BL, Melmon KL. Prothrombin time ratio and other factors associated with bleeding in patients treated with warfarin. J Clin Epidemiol 1989; 42(8): 759–64PubMedCrossRefGoogle Scholar
  31. 31.
    Panneerselvam S, Baglin C, Lefort W, et al. Analysis of risk factors for overanticoagulation in patients receiving long-term warfarin. Br J Haematol 1998; 103(2): 422–4PubMedCrossRefGoogle Scholar
  32. 32.
    White RH, McKittrick T, Takakuwa J, et al. Management and prognosis of life-threatening bleeding during warfarin therapy. National Consortium of Anticoagulation Clinics. Arch Intern Med 1996; 156(11): 1197–201PubMedCrossRefGoogle Scholar
  33. 33.
    Kuijer PM, Hutten BA, Prins MH, et al. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 1999; 159(5): 457–60PubMedCrossRefGoogle Scholar
  34. 34.
    Hylek EM, Heiman H, Skates SJ, et al. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA 1998; 279(9): 657–62PubMedCrossRefGoogle Scholar
  35. 35.
    Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353(9154): 717–9PubMedCrossRefGoogle Scholar
  36. 36.
    Hylek EM, Regan S, Go AS, et al. Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. Ann Intern Med 2001; 135(6): 393–400PubMedGoogle Scholar
  37. 37.
    White RH, McKittrick T, Hutchinson R, et al. Temporary discontinuation of warfarin therapy: changes in the international normalized ratio. Ann Intern Med 1995; 122(1): 40–2PubMedGoogle Scholar
  38. 38.
    Gadisseur AP, van der Meer FJ, Adriaansen HJ, et al. Therapeutic quality control of oral anticoagulant therapy comparing the short-acting acenocoumarol and the long-acting phenprocoumon. Br J Haematol 2002; 117(4): 940–6PubMedCrossRefGoogle Scholar
  39. 39.
    Watson HG, Baglin T, Laidlaw SL, et al. A comparison of the efficacy and rate of response to oral and intravenous vitamin K in reversal of over-anticoagulation with warfarin. Br J Haematol 2001; 115(1): 145–9PubMedCrossRefGoogle Scholar
  40. 40.
    Raj G, Kumar R, McKinney WP. Time course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytonadione. Arch Intern Med 1999; 159(22): 2721–4PubMedCrossRefGoogle Scholar
  41. 41.
    Lousberg TR, Witt DM, Beall DG, et al. Evaluation of excessive anticoagulation in a group model health maintenance organization. Arch Intern Med 1998; 158(5): 528–34PubMedCrossRefGoogle Scholar
  42. 42.
    Watson HG, Baglin TP, Makris M. The use of oral vitamin K for reversal of overwarfarinization [letter]. Br J Haematol 2002; 116(1): 237PubMedCrossRefGoogle Scholar
  43. 43.
    Fiore LD, Scola MA, Cantillon CE, et al. Anaphylactoid reactions to vitamin K. J Thromb Thrombolysis 2001; 11(2): 175–83PubMedCrossRefGoogle Scholar
  44. 44.
    Penning-van Beest FJ, Rosendaal FR, Grobbee DE, et al. Course of the International Normalized Ratio in response to oral vitamin K1 in patients overanticoagulated with phenprocoumon. Br J Haematol 1999; 104(2): 241–5CrossRefGoogle Scholar
  45. 45.
    Fondevila CG, Grosso SH, Santarelli MT, et al. Reversal of excessive oral anticoagulation with a low oral dose of vitamin K1 compared with acenocoumarine discontinuation: a prospective, randomized, open study. Blood Coagul Fibrinolysis 2001; 12(1): 9–16PubMedCrossRefGoogle Scholar
  46. 46.
    Pengo V, Banzato A, Garelli E, et al. Reversal of excessive effect of regular anticoagulation: low oral dose of phytonadione (vitamin K1) compared with warfarin discontinuation. Blood Coagul Fibrinolysis 1993; 4(5): 739–41PubMedGoogle Scholar
  47. 47.
    Shetty HG, Backhouse G, Bentley DP, et al. Effective reversal of warfarin-induced excessive anticoagulation with low dose vitamin K1. Thromb Haemost 1992; 67(1): 13–5PubMedGoogle Scholar
  48. 48.
    Brophy MT, Fiore LD, Deykin D. Low-dose vitamin K therapy in excessively anticoagulated patients: a dose-finding study. J Thromb Thrombolysis 1997; 4(2): 289–92PubMedCrossRefGoogle Scholar
  49. 49.
    Hung A, Singh S, Tait RC. A prospective randomized study to determine the optimal dose of intravenous vitamin K in reversal of over-warfarinization. Br J Haematol 2000; 109(3): 537–9PubMedCrossRefGoogle Scholar
  50. 50.
    Fetrow CW, Overlock T, Leff L. Antagonism of warfarin-induced hypoprothrombinemia with use of low-dose subcutaneous vitamin K1. J Clin Pharmacol 1997; 37(8): 751–7PubMedGoogle Scholar
  51. 51.
    Byrd DC, Stephens MA, Hamann GL, et al. Subcutaneous phytonadione for reversal of warfarin-induced elevation of the International Normalized Ratio. Am J Health Syst Pharm 1999; 56(22): 2312–5PubMedGoogle Scholar
  52. 52.
    Weibert RT, Le DT, Kayser SR, et al. Correction of excessive anticoagulation with low-dose oral vitamin K1. Ann Intern Med 1997; 126(12): 959–62PubMedGoogle Scholar
  53. 53.
    Crowther MA, Donovan D, Harrison L, et al. Low-dose oral vitamin K reliably reverses over-anticoagulation due to warfarin. Thromb Haemost 1998; 79(6): 1116–8PubMedGoogle Scholar
  54. 54.
    Wentzien TH, O’Reilly RA, Kearns PJ. Prospective evaluation of anticoagulant reversal with oral vitamin K1 while continuing warfarin therapy unchanged. Chest 1998; 114(6): 1546–50PubMedCrossRefGoogle Scholar
  55. 55.
    Pendry K, Bhavnani M, Shwe K. The use of oral vitamin K for reversal of over-warfarinization. Br J Haematol 2001; 113(3): 839–40PubMedCrossRefGoogle Scholar
  56. 56.
    Patel RJ, Witt DM, Saseen JJ, et al. Randomized, placebo-controlled trial of oral phytonadione for excessive anticoagulation. Pharmacotherapy 2000; 20(10): 1159–66PubMedCrossRefGoogle Scholar
  57. 57.
    Crowther MA, Julian J, McCarty D. Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial. Lancet 2000; 356(9241): 1551–3PubMedCrossRefGoogle Scholar
  58. 58.
    Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med 1997; 336(21): 1506–11PubMedCrossRefGoogle Scholar
  59. 59.
    Palareti G, Legnani C. Warfarin withdrawal: pharmacokinetic-pharmacodynamic considerations. Clin Pharmacokinet 1996; 30(4): 300–13PubMedCrossRefGoogle Scholar
  60. 60.
    Palareti G, Legnani C, Guazzaloca G, et al. Activation of blood coagulation after abrupt or stepwise withdrawal of oral anticoagulants: a prospective study. Thromb Haemost 1994; 72(2): 222–6PubMedGoogle Scholar
  61. 61.
    Genewein U, Haeberli A, Straub PW, et al. Rebound after cessation of oral anticoagulant therapy: the biochemical evidence. Br J Haematol 1996; 92(2): 479–85PubMedCrossRefGoogle Scholar
  62. 62.
    de la Rubia J, Grau E, Montserrat I, et al. Anaphylactic shock and vitamin K1 [letter]. Ann Intern Med 1989; 110(11): 943PubMedGoogle Scholar
  63. 63.
    Chung JY, Ramos-Caro FA, Beers B, et al. Hypersensitivity reactions to parenteral vitamin K. Cutis 1999; 63(1): 33–4PubMedGoogle Scholar
  64. 64.
    Gettler SL, Fung MA. Off-center fold: indurated plaques on the arms of a 52-year-old man. Diagnosis: cutaneous reaction to phytonadione injection. Arch Dermatol 2001; 137(7): 957–62PubMedGoogle Scholar
  65. 65.
    White RH, Minton SM, Andya MD, et al. Temporary reversal of anticoagulation using oral vitamin K. J Thromb Thrombolysis 2000; 10(2): 149–53PubMedCrossRefGoogle Scholar
  66. 66.
    Bonow RO, Carabello B, de Leon Jr AC, et al. Guidelines for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease). Circulation 1998; 98(18): 1949–84PubMedCrossRefGoogle Scholar
  67. 67.
    Gallus AS, Baker RI, Chong BH, et al. Consensus guidelines for warfarin therapy: recommendations from the Australasian Society of Thrombosis and Haemostasis. Med J Aust 2000; 172(12): 600–5PubMedGoogle Scholar
  68. 68.
    Haemotases and thombosis task force, British Society for Haematology. Guidelines on oral anticoagulation: third edition. Br J Haematol 1998; 101(2): 374–87CrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  1. 1.Department of Internal MedicineAmbroise Paré Hospital, Assistance Publique-Hôpitaux de ParisParisFrance
  2. 2.Université de VersaillesSaint-Quentin-en-YvelinesFrance

Personalised recommendations